SEC Comment Letter for ROCKET PHARMACEUTICALS, INC. (RCKT, RCKTW) (CIK 0001281895) (RCKT) — Oct 18, 2021

ROCKET PHARMACEUTICALS, INC. (RCKT, RCKTW) (CIK 0001281895)
Date: Oct. 18, 2021 · CIK: 0001281895 · Accession: 0000000000-21-012583

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-36829

Date

October 18, 2021

Author

Carlos Garcia-Parada

Form

UPLOAD

Company

ROCKET PHARMACEUTICALS, INC. (RCKT, RCKTW) (CIK 0001281895)

Letter

United States securities and exchange commission logo October 18, 2021 Carlos Garcia-Parada Chief Financial Officer Rocket Pharmaceuticals, Inc. 9 Cedarbrook Drive Cranbury, NJ 08512 Re:Rocket Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2020 Filed March 1, 2021 File No. 001-36829 Dear Mr. Garcia-Parada: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

United States securities and exchange commission logo
October 18, 2021
Carlos Garcia-Parada
Chief Financial Officer
Rocket Pharmaceuticals, Inc.
9 Cedarbrook Drive
Cranbury, NJ 08512
Re:Rocket Pharmaceuticals, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2020
Filed March 1, 2021
File No. 001-36829
Dear Mr. Garcia-Parada:
            We have completed our review of your filings.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io